The randomised, controlled, double-blind NOR-SWITCH study demonstrated that switching from originator infliximab to CT-P13 is efficacious and safe across six indications. However, a subgroup analysis of Crohn’s disease displayed a close to significant difference in terms of efficacy favouring originator infliximab.

This explorative subgroup analysis of Crohn’s disease and ulcerative colitis in the NOR-SWITCH main and extension trials displays comparable results regarding clinical, biochemical, immunogenicity, and patient-reported outcome measures between originator infliximab and CT-P13.

Long-term treatment with CT-P13 is efficacious and safe in inflammatory bowel disease.